These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33565043)

  • 1. Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
    Williams DM; Ruslan AM; Khan R; Vijayasingam D; Iqbal F; Shaikh A; Lim J; Chudleigh R; Peter R; Udiawar M; Bain SC; Stephens JW; Min T
    Diabetes Ther; 2021 Mar; 12(3):801-811. PubMed ID: 33565043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
    Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
    Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.
    Roy Chowdhury S; Sadouki F; Collins E; Keen F; Bhagi R; Lim YSJ; Cozma SL; Bain SC
    Diabetes Ther; 2024 Apr; 15(4):869-881. PubMed ID: 38427165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
    Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
    Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
    Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
    Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
    Brown RE; Bech PG; Aronson R
    Diabetes Obes Metab; 2020 Nov; 22(11):2013-2020. PubMed ID: 32538541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.
    Williams DM; Alberts BA; Sharaf A; Sharaf G; Bain SC; Kalhan A; Min T
    Diabetes Ther; 2024 Jul; 15(7):1639-1646. PubMed ID: 38722497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.
    Hepprich M; Zillig D; Florian-Reynoso MA; Donath MY; Rudofsky G
    Diabetes Ther; 2021 Mar; 12(3):943-954. PubMed ID: 33615400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study.
    Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH
    Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
    Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM
    Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study.
    van Houtum W; Schrömbges P; Amadid H; van Bon AC; Braae UC; Hoogstraten C; Herrings H
    Diabetes Ther; 2024 Aug; 15(8):1749-1768. PubMed ID: 38861137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
    Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study.
    Kick A; M'Rabet-Bensalah K; Acquistapace F; Amadid H; Ambühl RA; Braae UC; Item F; Schultes B; Züger T; Rudofsky G
    Diabetes Ther; 2024 Mar; 15(3):623-637. PubMed ID: 38240875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study.
    Holmes P; Bell HE; Bozkurt K; Catarig AM; Clark A; Machell A; Sathyapalan T
    Diabetes Ther; 2021 Nov; 12(11):2891-2905. PubMed ID: 34562237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.